H. pylori CagA-induced chronic inflammatory response is a strong risk factor for developing peptic ulcer and gastric cancer; therefore, inhibiting these inflammatory cascades is essential for managing H. pylori-associated gastric diseases. Here, S100A8 is linked to gastric cancer.